Month: April 2020

Jotun, der Orkla har en eierandel på 42,6 %, har offentliggjort en kvartalsoppdatering for perioden 1. januar – 31. mars 2020.Kvartalsoppdateringen er vedlagt denne meldingen.Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12VedleggJotun kvartalsoppdatering Q1-20

Prosafe and Total E&P UK Limited (‘Total’) have agreed to defer the commencement date for the Safe Caledonia to provide accommodation support at the Elgin complex in the UK sector of the North Sea by one year.The firm duration of the contract now commences around late Q1 2021 and remains as 162 days with one 30-day option. In addition, there will be a deferral fee payable by Total.Jesper Kragh Andresen, CEO of Prosafe says: “This contract remains important for both Prosafe and Total, even as we face a time of unprecedented challenge.”Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com

As announced on 27 March, Orkla publishes preliminary sales for the first quarter 2020 today. The complete and final results, including full P&L, balance sheet and cash flow statements, will be announced on 5 May.AttachmentOrkla Q1 2020 preliminary sales update ENG

Som annonsert 27. mars, offentliggjør Orkla i dag foreløpige salgstall for første kvartal 2020. Fullstendig og endelig resultat, inkludert resultatoppstilling, balanse og kontantstrøm, offentliggjøres 5. mai.VedleggOrkla Q1 2020 preliminary sales update NO

The shareholders of Anoto Group AB (publ) (the “Company”) are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on Monday, 18 May 2020 at 10 a.m. at the premises of Setterwalls Advokatbyrå, Sturegatan 10 in Stockholm, Sweden.Notification of participationShareholders wishing to attend the EGM mustbe entered as shareholders in the share register maintained by Euroclear Sweden AB no later than on Tuesday, 12 May 2020,notify the Company of their intention to participate no later than on Thursday, 14 May 2020.Attendance is to be notified by telephone +44 (0) 758 430 1260 or by e-mail to AGM@anoto.com. The notification should state name, social security number/corporate identification number and registered number of shares. To facilitate admittance to the EGM, proxies, registration certificates and other authorisation...

Aktieägarna i Anoto Group AB (publ) (“Bolaget”), kallas härmed till årsstämma att äga rum måndagen den 18 maj 2020, kl. 10.00 i Setterwalls Advokatbyrås lokaler med adress Sturegatan 10 i Stockholm. Rätt att delta och anmälanAktieägare som önskar att deltaga i bolagsstämman ska dels vara registrerad i eget namn i den av Euroclear Sweden AB förda aktieboken för Bolaget senast tisdagen den 12 maj 2020,dels anmäla sitt deltagande till Bolaget senast torsdagen den 14 maj 2020.Anmälan om deltagande i bolagsstämman ska ske per telefon +44 758 430 1260 eller via e-post till AGM@anoto.com. Vid anmälan ska namn, personnummer/organisationsnummer samt registrerat aktieinnehav uppges. Fullmakter, registreringsbevis och andra behörighetshandlingar bör för att underlätta inpasseringen vid stämman skickas till Bolaget via e-post till AGM@anoto.com senast...

Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis*Sanofi to host virtual scientific session April 23 from 8:00-9:00 am EST/ 2:00 – 3:00 pm CETPARIS – April 17, 2020 – Sanofi will host a scientific session to present detailed data from their Phase 2b trial evaluating its investigational BTK (Bruton’s tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule. In February, the company reported that the study’s primary endpoint was met, demonstrating that the BTK inhibitor significantly reduced disease activity associated with multiple sclerosis (MS) as measured by magnetic resonance imaging.“During these unprecedented times we remain committed to sharing results that allow us to advance the understanding of multiple sclerosis and the impact our...

Sanofi : Présentation des résultats détaillés de l’essai de phase II consacré à l’inhibiteur BTK à pénétration cérébrale dans le traitement de la sclérose en plaques rémittente-récurrente*Sanofi organisera une séance scientifique virtuelle le 23 avril de 8h00 à 9h00 EST/ 14h00 à 15h00 CETPARIS – Le 17 avril 2020 – Sanofi présentera les données détaillées de son essai de phase IIb consacré à son inhibiteur BTK (tyrosine kinase de Bruton) expérimental (SAR442168), une petite molécule sélective à pénétration cérébrale par voie orale, dans le cadre d’une séance scientifique virtuelle. En février, l’entreprise avait annoncé que le critère d’évaluation principal de l’étude avait été atteint et que l’inhibiteur BTK avait significativement réduit l’activité de la sclérose en plaques (SEP), telle que mesurée par imagerie par résonnance magnétique....